NA
RDY icon

Navellier & Associates’s Dr. Reddy's Laboratories RDY Stock Holding History

Navellier & Associates’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,355
Closed -$68K – 289
2015
Q3 		$68K Sell
5,355
-15,975
-75% -$198K 0.01% 258
2015
Q2 		$236K Buy
+21,330
New +$236K 0.02% 315

Other funds holding RDY

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Vontobel Asset Management New York $18.1B AUM 28.09% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Navellier & Associates's RDY Position: Q4 2015 in Review

Navellier & Associates sold out of Dr. Reddy's Laboratories (RDY) in Q4 2015, closing a stake of 5,355 shares — an estimated $68K sold.

Navellier & Associates first reported a position in RDY in Q2 2015 and held it in 2 quarters. The position peaked at $236K in Q2 2015. 174 funds tracked by Wall St. Rank hold RDY as of Q4 2015.

  • Navellier & Associates reported no remaining Dr. Reddy's Laboratories position as of Q4 2015 after selling out during the quarter.
  • Navellier & Associates sold 5,355 Dr. Reddy's Laboratories shares in Q4 2015, an estimated $68K.
  • Navellier & Associates first reported a position in Dr. Reddy's Laboratories in Q2 2015 and held it in 2 quarters.
  • Navellier & Associates's Dr. Reddy's Laboratories position peaked at $236K in Q2 2015.
  • 174 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q4 2015.

Based on Navellier & Associates's 13F filing for Q4 2015, filed 10 Feb 2016.